Wegener’s granulomatosis]); central nervous system or motor neur opathy considered of autoimmune origin (e.g. Guillain -Barre Syndrome, Myasthenia gravis, multiple sclerosis ). Patients with Graves’ , Hashimoto’s Disease , vitiligo, and diabetes type 1 will be allowed (12) Have any immunodeficiency disease or immune -compromised state (e.g. use of immunosuppressive agents) within 14 days prior to study enrollment (13) Have baseline coagulopathy > Grade 3 unless due to anticoagulant therapy Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 15 (14) Have peripheral neuropathy ≥ Grade 2 (15) Use of systemically -active steroids within 14 days prior t o enrollment in the study (16) Use of more than 3 grams per day of acetaminophen (17) Use of aspirin or other nonsteroidal anti -inflammatory drugs for 2 days before, during, and for 2 days after each administration of pemetrexed disodium (5 days before, during, and 2 days after each administration of pemetrexed disodium for piroxicam, naproxen, diflunisal, or nabumetone) (18) Have received t reatment with an investigational product within 28 days of study treatment or planned to receive within 28 days after vaccine administration . (19) Have k nown allergy to both penicillin and sulfa drugs (20) Have k nown or suspected allergy or hypersensitivity to yeast or any other component of CRS -207 (e.g. glycerol), Platinol or platinum -containing compounds, or pemetrexed (21) Have received a diagnosi s of human immunodeficiency virus ( HIV), hepatitis B, or hepatitis C (exception: clear evidence of natural immunity, immunity subsequent to vaccination, or successful eradication of the virus following antiviral therapy ) (22) Be a w oman who is pregnant or breastfeeding (23) Have prosthetic heart valves; major implant(s) or device(s) (e.g. artificial joints and prosthetics) placed within 12 months of study screening; or current or prior history of infection or clinically significant AEs associated with an exogenous implant(s) or device(s) that cannot be easily removed (24) Have had m ajor surgery or significant traumatic injury occurring within 28 days prior to CRS -207 administration or anticipated surgery or procedure requiring general anesthesia or deep sedation durin g study participation (including 28 days after last dose of CRS -207) (Minor procedures [dental work, skin biopsy, etc.], celiac plexus block, and biliary stents are allowed.) Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 16 (25) Have an unhealed wound which increases risk for bacterial infection (26) Be unable to avoid intimate contact with another individual known to be at high risk of listeriosis (e.g. newborn infant, pregnant female, etc.) for at least 7 days after receiving a CRS -207 infusion (27) Have an intercurrent illness that is either life -threatening or of cl inical significance such that it might limit compliance with study requirements (including, but not limited to, ongoing or active infection, metabolic [e.g. diabetes] or neurologic disease, peripheral vascular disease, or psychiatric illness/social situations) (28) Have insufficient peripheral venous access to permit completion of the study dosing and compliance with study phlebotomy regimen (29) Have a history of alcohol dependence or use of illicit drugs that could potentially interfere with adherence to study proc edures or requirements (e.g. opioids, cocaine, amphetamines, hallucinogens, etc.) 3.2.3 Dosing Eligibility Subjects must have adequate organ function as defined by the laboratory values in Table 1 before each dose of CRS -207 in Cohort 1 or Cy in Cohort 2. Laboratory tests may be done up to 3 days prior to CRS -207 dosing (Cohort 1) or 2 days prior to Cy dosing for subjects receiving Cy (Cohort 2 ). Subjects who do not meet the dosing- eligibility requirements will be monitored.